Market Place
Sourcing Support
Pharmacosmos And G1 Therapeutics Close Tender Offer
18 Sep 2024 //
GLOBENEWSWIRE
Trilaciclib Combination Shows Survival, Tolerability Benefit In Study
28 May 2024 //
GLOBENEWSWIRE
G1 Therapeutics to Continue Phase 3 Trial of Trilaciclib in Breast Cancer
12 Feb 2024 //
GLOBENEWSWIRE
Data Indicate Trilaciclib Reduces Hospitalizations and Myelosuppressive Events
27 Oct 2023 //
GLOBENEWSWIRE
G1 Therapeutics COSELA Recommended in Updated Small Cell Lung Cancer Guidelines
18 Oct 2023 //
GLOBENEWSWIRE
Publication Highlights Impact of Trilaciclib on Myelosuppressive Events
31 Jul 2023 //
GLOBENEWSWIRE
G1 Therapeutics to halt drug trial in colon cancer, shares plunge
14 Feb 2023 //
REUTERS
First Prescription for COSELA® (trilaciclib) Issued in China
09 Feb 2023 //
PR NEWSWIRE
G1 Therapeutics Announces Readouts from PII & PIII Trials of Trilaciclib
09 Jan 2023 //
GLOBENEWSWIRE
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib
02 Nov 2022 //
GLOBENEWSWIRE
G1 Therapeutics Completes Enrollment in Global Ph3 Trial of Trilaciclib
10 Oct 2022 //
GLOBENEWSWIRE
G1 Therapeutics Completes Enrollment in PIII Trial of Trilaciclib in mCC
13 Jun 2022 //
GLOBENEWSWIRE
Data Presented at ASCO Say Trilaciclib Helps Against Severe Issues in ES-SCLC
02 Jun 2022 //
GLOBENEWSWIRE
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials
18 Apr 2022 //
PRNEWSWIRE
Real-World Data Show Potential of Trilaciclib to Reduce Myelosuppression in SCLC
31 Mar 2022 //
GLOBENEWSWIRE
G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
16 Dec 2021 //
GLOBENEWSWIRE
Analysis from Phase 2 TNBC Trial Shows Enhanced Patients’ T Cell Immune Function
12 Nov 2021 //
GLOBENEWSWIRE
G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
15 Sep 2021 //
GLOBENEWSWIRE
ICER to Assess Novel Agents to Prevent Chemotherapy-Induced Neutropenia
25 Aug 2021 //
ICER
G1 Therapeutics and BI Announce Commercial Availability of COSELA™
02 Mar 2021 //
GLOBENEWSWIRE
New Drug OK`d for Chemo-Induced Myelosuppression in SCLC
15 Feb 2021 //
MEDPAGETODAY
G1 Therapeutics to Present Data on Trilaciclib at (NACLC)
14 Oct 2020 //
BIOSPACE
G1 Therapeutics to Present Showing Myelopreservation Benefits of Trilaciclib
13 May 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.